Evidence map›Paper›PMID 24348057›Full record

ArticleClinicoEconomics and outcomes research : CEOR2013

C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia.

Claudio Mencacci, Eugenio Aguglia, Giovanni Biggio, Lodovico Cappellari, Guido Di Sciascio, Andrea Fagiolini, Giuseppe Maina, Alfonso Tortorella, Pablo Katz, Claudio Ripellino

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ClinicoEconomics and outcomes research : CEOR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Claudio MencacciDepartment of Mental Health, Fatebenefratelli Hospital, Milan, Italy.
Eugenio AgugliaDepartment of Clinical and Molecular Biomedicine, University of Catania, Catania, Italy.
Giovanni BiggioDepartment of Experimental Biology and Center of Excellence for the Neurobiology of Drug Dependence, University of Cagliari, Calgiari, Italy.
Lodovico CappellariDepartment of Mental Health, Camposampiero Hospital, Padova, Italy.
Guido Di SciascioDepartment of Psychiatry, Policlinico Hospital, Bari, Italy.
Andrea FagioliniDepartment of Molecular Medicine, University of Siena and Department of Mental Health, University of Siena Medical Center, Siena, Italy.
Giuseppe MainaDepartment of Neurosciences, University of Torino, Torino, Italy.
Alfonso TortorellaDepartment of Mental Health, University of Naples SUN, Naples, Italy.
Pablo KatzCSD Medical Research Srl, Milan, Italy.
Claudio RipellinoCSD Medical Research Srl, Milan, Italy.
Fatebenefratelli Hospital · ITUniversity of Catania · ITUniversity of Naples Federico II · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMajor depression is a commonly occurring, seriously impairing, and often recurrent mental disorder. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the treatments most commonly used for major depressive disorder. The objective of this study was to assess the cost-effectiveness of SSRIs and SNRIs in the treatment of major depressive disorder in two Italian regional settings, ie, Veneto and Sardinia.

methodsA decision analytic model was adapted from the Swedish Dental and Pharmaceutical Benefits Agency to reflect current clinical practice in the treatment of major depressive disorder in the most significant Italian regions. This adaptation was possible as a result of collaboration with an expert panel of Italian psychiatrists and health economists. The population comprised patients with a first diagnosis of major depressive disorder and initiating one SSRI or SNRI drug for the first time. The time frame used was 12 months. Efficacy and utility data for the model were retrieved from the literature and validated by the expert panel. Local data were used for resource utilization and for treatment costs based on the perspective of each regional health service. Scenario analyses and probabilistic sensitivity analyses were performed to test the robustness of the model.

resultsBase case analysis showed that escitalopram is associated with the largest health gain (in quality-adjusted life years) and a lower total cost at one year for Sardinia (except for sertraline, against which it was cost-effective) and for Veneto, and therefore dominates the other treatment strategies, given that more quality-adjusted life years are achieved at a lower total cost. Scenario analyses and probabilistic sensitivity analyses support the robustness of the model.

conclusionThe results indicate that escitalopram is the most cost-effective pharmacologic treatment strategy for both regional health services compared with all SSRIs and all SNRIs used in the first-line treatment of major depressive disorder.

Indexed as

antidepressantscost-effectiveness quality of lifeItalymajor depressive disorder

Identifiers

PMID24348057
PMCPMC3857011
OpenAlexW2004855887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.